A method for treating infection, sepsis and injury

Abstract

The invention relates to a composition or method for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of infection, sepsis and injury. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic.

1 . A method for treating sepsis and sepsis related vulnerabilities comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic to a subject in need thereof. 
     
     
         2 . A method according to  claim 1 , wherein the method is for treating sepsis. 
     
     
         3 . A method according to  claim 1 , in which component (i) is an adenosine receptor agonist. 
     
     
         4 . A method according to  claim 3 , in which the adenosine receptor agonist is adenosine or a derivative thereof. 
     
     
         5 . A method according to  claim 4 , in which the concentration of adenosine or a derivative thereof in the composition is 0.0000001 mM to 100 mM. 
     
     
         6 . A method according to  claim 1 , in which component (ii) is lidocaine or a derivative thereof. 
     
     
         7 . A method according to  claim 6 , in which the concentration of lidocaine or a derivative thereof in the composition is 0.0000001 mM to 100 mM. 
     
     
         8 . A method according to  claim 1 , which further comprises administration of a citrate. 
     
     
         9 . A method according to  claim 8 , in which the citrate is selected from citrate phosphate dextrose (CPD), magnesium citrate, sodium citrate, potassium citrate and sildenafil citrate. 
     
     
         10 . (canceled) 
     
     
         11 . A method according to  claim 1 , which further comprises the administration of a source of magnesium. 
     
     
         12 . A method according to  claim 11 , in which the concentration of the source of magnesium is 2000 mM or less. 
     
     
         13 . A method according to  claim 1 , which further comprises the administration of an anti-inflammatory agent. 
     
     
         14 . A method according to  claim 1 , which further comprises the administration of a pharmaceutically acceptable carrier. 
     
     
         15 . A method according to  claim 13 , in which the pharmaceutically acceptable carrier comprises a buffer. 
     
     
         16 . A method according to  claim 1 , which comprises the administration of 0.1 to 40 mM of adenosine, 0.1 to 80 mM of lidocaine or a salt thereof, 0.1 to 2000 mM of a source of magnesium, 0.1 to 20 mM of a citrate and 0.9 to 3% of an ionic solution. 
     
     
         17 . A method according to  claim 1 , in which components (i) and (ii) are administered simultaneously, sequentially or separately. 
     
     
         18 . A method according to  claim 16 , wherein the components (i) and (ii) are administered in one shot as a bolus or in two steps as a bolus followed by infusion. 
     
     
         19 .- 20 . (canceled) 
     
     
         21 . A kit for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of infection, sepsis and injury comprising (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic in which components (i) and (ii) are held separately and the kit is adapted to ensure simultaneous or sequential administration of components (i) and (ii). 
     
     
         22 . A method for treating infection comprising the administration of (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic to a subject in need thereof.